Recurrent/Metastatic Adenoid Cystic Carcinoma Treated with Axitinib and Avelumab

Data from patients with adenoid cystic carcinoma treated with combination of VEGFR inhibitor axitinib and anti-PD-L1 avelumab. Eligible patients had R/M ACC with progression within 6 months before enrollment. The primary end point was objective response rate (ORR) per RECIST 1.1; secondary end points included progression-free survival (PFS), overall survival (OS), and toxicity. The study reached its primary end point with ≥4 PRs in 28 evaluable patients (confirmed ORR of 18%).

• Type: Exome Sequencing
• Archiver: European Genome-phenome Archive (EGA)